top of page
AI pixabay huge.jpg

Pharma cos now demanding return on digital investments but some still risk being left behind

Cajoled by the pandemic and ongoing challenges with clinical trials, including studies’ low rates of technical success, protracted timelines, recruitment and retention failures, as well as ever-increasing pressures to find new revenue streams as patent cliffs draw near, drugmakers now want to see digital investments bearing fruit.



Comments


bottom of page